Interview with Longevity Technology

Osteoarthritis affects one in seven adults in the US, with more than half of patients of working age. There are currently no effective and well tolerated oral therapies that provide long term relief for the symptoms of OA or reduce its progression. With APPA, AKL believes it has the only drug with a mechanism of action that targets the multiple signaling pathways in bone, cartilage and inflammation that are involved in OA.

To learn more, Longevity Technology caught up with the company’s CSO, Alan Reynolds. A full copy of the interview can be found at AKL combines synthesized plant metabolites to create promising oral OA treatment